These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 25127039)

  • 1. IGFBP3 methylation is a novel diagnostic and predictive biomarker in colorectal cancer.
    Perez-Carbonell L; Balaguer F; Toiyama Y; Egoavil C; Rojas E; Guarinos C; Andreu M; Llor X; Castells A; Jover R; Boland CR; Goel A
    PLoS One; 2014; 9(8):e104285. PubMed ID: 25127039
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Relevance of Plasma DNA Methylation in Colorectal Cancer Patients Identified by Using a Genome-Wide High-Resolution Array.
    Lin PC; Lin JK; Lin CH; Lin HH; Yang SH; Jiang JK; Chen WS; Chou CC; Tsai SF; Chang SC
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1419-27. PubMed ID: 25472652
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IGFBP3 gene promoter methylation analysis and its association with clinicopathological characteristics of colorectal carcinoma.
    Kumar A; Singh P; Pandey A; Gosipatala SB
    Mol Biol Rep; 2020 Sep; 47(9):6919-6927. PubMed ID: 32929656
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DNA Hypermethylation of SHISA3 in Colorectal Cancer: An Independent Predictor of Poor Prognosis.
    Tsai MH; Chen WC; Yu SL; Chen CC; Jao TM; Huang CY; Tzeng ST; Yen SJ; Yang YC
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1481-9. PubMed ID: 25968618
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Promoter CpG island methylation of RET predicts poor prognosis in stage II colorectal cancer patients.
    Draht MX; Smits KM; Tournier B; Jooste V; Chapusot C; Carvalho B; Cleven AH; Derks S; Wouters KA; Belt EJ; Stockmann HB; Bril H; Weijenberg MP; van den Brandt PA; de Bruïne AP; Herman JG; Meijer GA; Piard F; Melotte V; van Engeland M
    Mol Oncol; 2014 May; 8(3):679-88. PubMed ID: 24560444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel DNA methylation panel accurately detects colorectal cancer independently of molecular pathway.
    Freitas M; Ferreira F; Carvalho S; Silva F; Lopes P; Antunes L; Salta S; Diniz F; Santos LL; Videira JF; Henrique R; Jerónimo C
    J Transl Med; 2018 Feb; 16(1):45. PubMed ID: 29486770
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NKX6.1 hypermethylation predicts the outcome of stage II colorectal cancer patients undergoing chemotherapy.
    Chang SY; Kuo CC; Wu CC; Hsiao CW; Hu JM; Hsu CH; Chou YC; Shih YL; Lin YW
    Genes Chromosomes Cancer; 2018 May; 57(5):268-277. PubMed ID: 29363224
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Colorectal cancer molecular classification using BRAF, KRAS, microsatellite instability and CIMP status: Prognostic implications and response to chemotherapy.
    Murcia O; Juárez M; Rodríguez-Soler M; Hernández-Illán E; Giner-Calabuig M; Alustiza M; Egoavil C; Castillejo A; Alenda C; Barberá V; Mangas-Sanjuan C; Yuste A; Bujanda L; Clofent J; Andreu M; Castells A; Llor X; Zapater P; Jover R
    PLoS One; 2018; 13(9):e0203051. PubMed ID: 30188916
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IGFBP3 promoter methylation in colorectal cancer: relationship with microsatellite instability, CpG island methylator phenotype, and p53.
    Kawasaki T; Nosho K; Ohnishi M; Suemoto Y; Kirkner GJ; Fuchs CS; Ogino S
    Neoplasia; 2007 Dec; 9(12):1091-8. PubMed ID: 18084616
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The CpG island methylator phenotype may confer a survival benefit in patients with stage II or III colorectal carcinomas receiving fluoropyrimidine-based adjuvant chemotherapy.
    Min BH; Bae JM; Lee EJ; Yu HS; Kim YH; Chang DK; Kim HC; Park CK; Lee SH; Kim KM; Kang GH
    BMC Cancer; 2011 Aug; 11():344. PubMed ID: 21827707
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CHFR promoter methylation indicates poor prognosis in stage II microsatellite stable colorectal cancer.
    Cleven AH; Derks S; Draht MX; Smits KM; Melotte V; Van Neste L; Tournier B; Jooste V; Chapusot C; Weijenberg MP; Herman JG; de Bruïne AP; van Engeland M
    Clin Cancer Res; 2014 Jun; 20(12):3261-71. PubMed ID: 24928946
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serrated colorectal cancer: Molecular classification, prognosis, and response to chemotherapy.
    Murcia O; Juárez M; Hernández-Illán E; Egoavil C; Giner-Calabuig M; Rodríguez-Soler M; Jover R
    World J Gastroenterol; 2016 Apr; 22(13):3516-30. PubMed ID: 27053844
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A prognostic CpG score derived from epigenome-wide profiling of tumor tissue was independently associated with colorectal cancer survival.
    Jia M; Zhang Y; Jansen L; Walter V; Edelmann D; Gündert M; Tagscherer KE; Roth W; Bewerunge-Hudler M; Herpel E; Kloor M; Ulrich A; Burwinkel B; Bläker H; Chang-Claude J; Brenner H; Hoffmeister M
    Clin Epigenetics; 2019 Jul; 11(1):109. PubMed ID: 31340858
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Methylator phenotype in colorectal cancer: A prognostic factor or not?
    Gallois C; Laurent-Puig P; Taieb J
    Crit Rev Oncol Hematol; 2016 Mar; 99():74-80. PubMed ID: 26702883
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Underexpression of LATS1 TSG in colorectal cancer is associated with promoter hypermethylation.
    Wierzbicki PM; Adrych K; Kartanowicz D; Stanislawowski M; Kowalczyk A; Godlewski J; Skwierz-Bogdanska I; Celinski K; Gach T; Kulig J; Korybalski B; Kmiec Z
    World J Gastroenterol; 2013 Jul; 19(27):4363-73. PubMed ID: 23885148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aberrant promoter methylation of PPP1R3C and EFHD1 in plasma of colorectal cancer patients.
    Takane K; Midorikawa Y; Yagi K; Sakai A; Aburatani H; Takayama T; Kaneda A
    Cancer Med; 2014 Oct; 3(5):1235-45. PubMed ID: 24861485
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Microsatellite instability, MLH1 promoter methylation, and BRAF mutation analysis in sporadic colorectal cancers of different ethnic groups in Israel.
    Vilkin A; Niv Y; Nagasaka T; Morgenstern S; Levi Z; Fireman Z; Fuerst F; Goel A; Boland CR
    Cancer; 2009 Feb; 115(4):760-9. PubMed ID: 19127559
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinicopathological predictors of benefit from adjuvant chemotherapy for stage C colorectal cancer: Microsatellite unstable cases benefit.
    Thomas ML; Hewett PJ; Ruszkiewicz AR; Moore JW
    Asia Pac J Clin Oncol; 2015 Dec; 11(4):343-51. PubMed ID: 26471980
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation between hypermethylation of the RASSF2A promoter and K-ras/BRAF mutations in microsatellite-stable colorectal cancers.
    Park HW; Kang HC; Kim IJ; Jang SG; Kim K; Yoon HJ; Jeong SY; Park JG
    Int J Cancer; 2007 Jan; 120(1):7-12. PubMed ID: 17013898
    [TBL] [Abstract][Full Text] [Related]  

  • 20. p16INK4a gene promoter hypermethylation in mucosa as a prognostic factor for patients with colorectal cancer.
    Wettergren Y; Odin E; Nilsson S; Carlsson G; Gustavsson B
    Mol Med; 2008; 14(7-8):412-21. PubMed ID: 18418463
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.